Immunotherapy has the potential to provide long-term benefits to certain lung cancer patients; however, certain patients may not respond, while others who initially respond may develop resistance. In this interview, Alastair Greystoke, PhD, of the University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses how we can overcome this issue. Dr Greystoke highlights the use of additional drugs in combination regimens and predicts what approach this may take in future. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.
Checkpoint inhibitors for lung cancer: combating resistance
